Relmada Therapeutics (Relmada Therapeutics) Days Inventory : 0.00 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Relmada Therapeutics Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Relmada Therapeutics's Average Total Inventories for the three months ended in Mar. 2024 was $0.00 Mil. Relmada Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for Relmada Therapeutics's Days Inventory or its related term are showing as below:

During the past 11 years, Relmada Therapeutics's highest Days Inventory was 410.63. The lowest was 410.63. And the median was 410.63.

RLMD's Days Inventory is not ranked ^*
in the Biotechnology industry.
Industry Median: 190.92
* Ranked among companies with meaningful Days Inventory only.

Relmada Therapeutics's Days Inventory stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Relmada Therapeutics Days Inventory Historical Data

The historical data trend for Relmada Therapeutics's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics Days Inventory Chart

Relmada Therapeutics Annual Data

Trend

Aug13

Jun15

Jun16

Jun17

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

Days Inventory

Get a 7-Day Free Trial

Relmada Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Relmada Therapeutics's Days Inventory

For the Biotechnology subindustry, Relmada Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relmada Therapeutics's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's Days Inventory distribution charts can be found below:

* The bar in red indicates where Relmada Therapeutics's Days Inventory falls into.

Relmada Therapeutics Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Relmada Therapeutics's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

	Days Inventory (A: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Relmada Therapeutics's Days Inventory for the quarter that ended in Mar. 2024 is calculated as:

	Days Inventory (Q: Mar. 2024 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Dec. 2023 )	+	Total Inventories (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Relmada Therapeutics (NAS:RLMD) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Relmada Therapeutics's Inventory Turnover for the three months ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Relmada Therapeutics's Inventory to Revenue for the three months ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Relmada Therapeutics Days Inventory Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Relmada Therapeutics (Relmada Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (NAS:RLMD) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

4E2:Germany

Address

2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134

Website

https://www.relmada.com

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Executives

Cedric O'gorman	officer: Chief Medical Officer	C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Fabiana Fedeli	director	C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Sergio Traversa	director, officer: Chief Executive Officer	138 CANTERBURY LN, BLUE BELL PA 19422
Paul Edward Kelly	director	300 EAST 56TH STREET, APT 19E, NEW YORK, NY 10022
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
Maged Shenouda	director	305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Thomas Wessel	officer: EVP, Head of R&D	15 SKYLINE DRIVE, HAWTHORNE NY 10532
Eric Thomas Schmidt	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Glasspool	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Chuck Ence	officer: Chief Financial Officer	3000 S. UNIVERSITY BLVD., DENVER CO 80210
Ottavio V. Vitolo	officer: Chief Medical Officer	71 WESTLAND AVENUE, NEWTON MA 02465
Shreeram Agharkar	director	P.O BOX 2042, PRINCETON NJ 08543
Sandesh Seth	director	300 E 93RD STREET, #20-B, NEW YORK NY 10128
Lisa Nolan	officer: Chief Business Officer	36 ROCKLAND MILLS, ROCKLAND DE 19732
Eliseo Oreste Salinas	officer: President and CSO	7707 GATEWAY BLVD, NEWARK CA 94560